Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors
Patent No. EP2432454 (titled "Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors") was filed by Neuroderm on May 17, 2010. The application was issued on Mar 1, 2017.
Patent Summary
Compositions for continuously delivering dopamine precursor levodopa to treat Parkinson's disease without pulsatile levodopa levels. The compositions contain a stable liquid formulation of levodopa and its decarboxylase inhibitor carbidopa, along with arginine. The arginine salt of carbidopa allows higher concentrations of both drugs in a liquid formulation. The formulation has specific ratios of levodopa:arginine:carbidopa molar ratios, pH, and stability. Continuous administration of the levodopa/carbidopa/arginine formulation along with discrete oral levodopa reduces pulsatility and improves efficacy compared to oral levodopa alone.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP2432454
- Application Number
- EP10725880A
- Filing Date
- May 17, 2010
- Status
- Opposition Rejected
- Dec 6, 2019
- Publication Date
- Mar 1, 2017
- External Links
- Slate, Register , Google Patents